RE: Possible trade sell6 Jun 2021 14:24
Re : preclinical molecules being licenced out to big pharma.C4xd on aim has two so far.One with indivior currently in phase 1 and another just recently licenced out with Sanofi with over 700 mill I believe in future milestone and royalty payments if all goes to plan.If you look at c4xd’s marketcap, the probability of future clinical success combined with value of time and dilution is seriously discounting the potential future cash flow.Their mcap is half sclp’s.Different company and strategy but personally I wouldn’t want a buyout here yet.
Something similar to more of a partnership like biontech achieved would be amazing or obviously cepi would be an amazing too. An optimal result in my opinion.
I’m not sure when might be an optimal time to consider selling if not partnered.I have a vague feeling some small cap pharma sell after phase 2, (as I’m assuming more is proven up to big pharma and the risk of phase 3 is taken on by big pharma), who can handle it better).Though I’m just guessing actually. Anyone know?
Resmile should be in a position to know what to do when and with the best potential future funding routes.Great to have those guys involved as the scientists aren’t venture capitalists with financial contacts and expertise naturally.It lets them get on with what they naturally do best.